The goal of the SPORE in Endometrial Cancer Developmental Research Program (DRP) is to recruit and support developmental research projects in endometnal cancer for future incorporation as full SPORE projects or application for other major peer-review funding. The types of studies to be supported include projects in basic research, clinical research, epidemiologic studies, and cancer prevention and control research in endometnal cancer. Projects will expand the scope of translational research and increase the number of investigators committed to Endometnal cancer. This program will be open to all of the participating institutions in the SPORE and any of their collaborators. In addition, plans in year 2 call for development of new projects with other SPOREs. This program along with the Career Development Program is consistent with the Siteman Cancer Center's overall commitment to the recruitment of minority investigators. New research projects will be solicited and funded through developmental funds. Two to three developmental projects will be funded each year throughout the life of the SPORE. Requests For Applications (RFA) for developmental projects in Endometnal cancer research will be requested once per year. All developmental project applications will be reviewed by a Research Development Committee consisting of seven scientists (representing basic and applied science) with expertise in Endometrial, or related cancers or relevant science, a biostatistician, a patient advocate, and ad hoc members, as necessary (special expertise, no conflict of interest). This committee will make recommendations to the Endometnal SPORE Steering Committee, which will make final decisions.

Public Health Relevance

The work proposed will lead to both an improved understanding of endometrial cancer biology and new approaches to the detection, prevention and treatment of uterine cancers which will result in reduced cancer morbidity and mortality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA134254-01A1
Application #
7727366
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2009-09-18
Project End
2012-08-31
Budget Start
2009-09-18
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$19,394
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180
Li, Jing; Xing, Xiaoyun; Li, Daofeng et al. (2017) Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. Neoplasia 19:100-111
Jeske, Yvette W; Ali, Shamshad; Byron, Sara A et al. (2017) FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:366-373
McMeekin, D Scott; Tritchler, David L; Cohn, David E et al. (2016) Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 34:3062-8
Rocconi, Rodney P; Lankes, Heather A; Brady, William E et al. (2016) The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 140:264-9
Goodfellow, Paul J; Billingsley, Caroline C; Lankes, Heather A et al. (2015) Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol 33:4301-8
Frolova, Antonina I; Babb, Sheri A; Zantow, Emily et al. (2015) Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. Gynecol Oncol 137:7-13
Huang, Yi-Wen; Kuo, Chieh-Ti; Chen, Jo-Hsin et al. (2014) Hypermethylation of miR-203 in endometrial carcinomas. Gynecol Oncol 133:340-5
Powell, Matthew A; Sill, Michael W; Goodfellow, Paul J et al. (2014) A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:38-43
Wang, Li-Shu; Burke, Carol A; Hasson, Henrietta et al. (2014) A phase Ib study of the effects of black raspberries on rectal polyps in patients with familial adenomatous polyposis. Cancer Prev Res (Phila) 7:666-74

Showing the most recent 10 out of 34 publications